Answers are grounded in this paper and cite their sources.
Graphical abstract A cellular protease-mediated graphene-based nanosystem is developed for co-delivery of a membrane-associated cytokine (TRAIL) and an intracellular-acting small-molecule drug (DOX). The nanocarrier realizes the intramembrane enzyme-mediated extracellular release of TRAIL and endocytotic acidity-responsive intracellular release of DOX, which enables them to target to their distinct sites of action. This formulation starts a new generation of 2D nanomaterials with programmed-release therapeutics capability for combination cancer treatment.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: